FY2025 EPS Estimates for Alvotech Lowered by Northland Capmk

Alvotech (NASDAQ:ALVO - Free Report) - Stock analysts at Northland Capmk cut their FY2025 earnings per share estimates for Alvotech in a research report issued to clients and investors on Thursday, April 10th. Northland Capmk analyst C. Byrnes now anticipates that the company will post earnings per share of $0.00 for the year, down from their previous estimate of $0.05. The consensus estimate for Alvotech's current full-year earnings is ($0.07) per share.

Separately, UBS Group started coverage on shares of Alvotech in a research report on Friday, February 14th. They set a "buy" rating and a $18.00 target price on the stock.

Alvotech Trading Up 0.8 %

ALVO traded up $0.07 during trading hours on Monday, hitting $8.60. The company's stock had a trading volume of 61,596 shares, compared to its average volume of 137,335. The stock has a market cap of $2.59 billion, a price-to-earnings ratio of -4.65 and a beta of -0.05. The business's 50-day moving average price is $10.91 and its 200-day moving average price is $11.95. Alvotech has a 12 month low of $7.35 and a 12 month high of $14.76.

Alvotech (NASDAQ:ALVO - Get Free Report) last issued its earnings results on Wednesday, March 26th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.74) by $0.50. The firm had revenue of $153.34 million during the quarter, compared to the consensus estimate of $97.99 million.

Remove Ads

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ALVO. GF Fund Management CO. LTD. purchased a new stake in Alvotech in the 4th quarter worth about $74,000. Vident Advisory LLC bought a new stake in shares of Alvotech during the fourth quarter worth $268,000. PointState Capital LP grew its holdings in shares of Alvotech by 64.1% in the fourth quarter. PointState Capital LP now owns 1,241,379 shares of the company's stock worth $16,423,000 after purchasing an additional 484,826 shares during the last quarter. ProShare Advisors LLC purchased a new position in Alvotech in the 4th quarter worth about $167,000. Finally, Bank of America Corp DE lifted its holdings in Alvotech by 19.7% during the 4th quarter. Bank of America Corp DE now owns 16,240 shares of the company's stock valued at $215,000 after buying an additional 2,677 shares in the last quarter.

Alvotech Company Profile

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass.